Neurology
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Servier’s acquisition of Edgewise’s muscular dystrophy business shows that rare neuromuscular disease is no longer a side market. The next test is whether investment becomes diagnosis, referral and access.
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Huntington’s Disease Gets an Oral Target-Engagement Signal
A Urine Test for Alzheimer’s Would Change the Access Conversation
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
AI in Cardiology Moves From Promise to Policy Pressure
Cyberbullying Becomes a Youth Mental Health Policy Target
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Rare Epilepsy Moves Toward Treating the Cause
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.